ContraFect (NASDAQ:CFRX) Announces Quarterly Earnings Results

ContraFect (NASDAQ:CFRX) released its earnings results on Tuesday. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.01, Bloomberg Earnings reports.

Shares of NASDAQ:CFRX traded down $0.01 on Wednesday, hitting $0.30. The company had a trading volume of 40,600 shares, compared to its average volume of 742,785. The firm’s 50-day simple moving average is $0.34 and its two-hundred day simple moving average is $0.42. ContraFect has a 1 year low of $0.27 and a 1 year high of $2.63. The company has a quick ratio of 4.15, a current ratio of 4.15 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $24.74 million, a price-to-earnings ratio of -0.81 and a beta of 0.17.

Several equities research analysts have recently commented on the stock. ValuEngine raised shares of ContraFect from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Maxim Group reaffirmed a “buy” rating and issued a $2.00 target price on shares of ContraFect in a research report on Friday, October 4th.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Featured Article: After-Hours Trading

Earnings History for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with's FREE daily email newsletter.